Saturday 17 October 2026
Export TENX’s income statement to Excel — free account
Tenax Therapeutics, Inc.
TENX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 29.6% and free cash flow fell 125.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.36
0.15
−9.93%
Follow TENX
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
2.20 | 7.99 | 8.51 | 2.44 | 3.21 | 3.64 | 1.74 | 3.26 | 20.60 | 14.57 |
Net Debt/EBITDA |
0.26 | 0.86 | 1.89 | 0.64 | 0.69 | 0.17 | 0.19 | 1.19 | 4.87 | 1.73 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.36 | 1.37 | 0.39 | 0.90 | 0.94 | 0.33 | 1.03 | 0.77 | 0.84 | 0.68 |
Capex/Depreciation |
0.11 | (0.02) | (0.08) | (0.03) | (0.03) | (0.04) | (0.02) | 0.38 | — | — |
Interest Coverage |
(134.31) | (52.91) | (86.17) | (59.41) | (3,083.72) | (18,182.33) | (2,511.95) | (343.08) | (847.57) | — |
| (113.26%) | (67.94%) | (136.97%) | (108.01%) | (234.61%) | (732.21%) | (385.12%) | (160.80%) | (35.17%) | (55.64%) | |
| (91.20%) | (53.20%) | (121.79%) | (85.21%) | (148.88%) | (505.01%) | (235.14%) | (102.20%) | (32.48%) | (52.36%) | |
ROIC |
(852.44%) | (498.28%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(589.73%) | (125.14%) | (120.24%) | (229.67%) | (210.39%) | (785.91%) | (807.65%) | (95.23%) | (19.13%) | (54.19%) |
Average Days of Receivables |
0.00 | 0.00 | — | — | — | — | — | — | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(17,554.67) | (13,494.44) | (5,507.10) | (1,938.41) | (1,427.14) | (841.98) | (619.07) | (23.79) | (0.97) | (0.91) |
Cash per Share |
14,756.22 | 8,585.78 | 12,862.00 | 1,384.59 | 1,032.75 | 432.86 | 115.42 | 39.48 | 6.21 | 2.49 |
Shareholders Equity per Share |
19,045.44 | 9,868.78 | 11,771.50 | 967.31 | 711.63 | 329.05 | 81.13 | 32.65 | 6.02 | 2.48 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
19,045.44 | 9,868.78 | 11,771.50 | 967.31 | 711.63 | 329.05 | 81.13 | 32.65 | 6.02 | 2.48 |
Free Cash Flow |
(15.80) | (12.14) | (5.51) | (7.56) | (9.28) | (10.86) | (11.39) | (5.90) | (14.81) | (35.80) |
Working Capital |
7.43 | 7.05 | 11.75 | 3.65 | 4.68 | 4.13 | 1.36 | 8.10 | 91.99 | 97.07 |
Capital Expenditures |
0.07 | 0.00 | (0.01) | 0.00 | 0.00 | (0.01) | 0.00 | 0.00 | — | — |
Net Current Asset Value |
7.43 | 7.05 | 11.75 | 3.59 | 4.55 | 3.94 | 1.30 | 8.10 | 91.99 | 97.07 |
| Other line items | ||||||||||
Quick Ratio |
2.15 | 7.71 | 8.21 | 2.13 | 3.17 | 3.57 | 1.15 | 2.73 | 20.21 | 13.63 |
Depreciation/Fixed assets |
35.17 | 20.31 | 11.82 | 16.06 | 20.30 | 16.68 | 15.74 | 0.00 | — | — |
Cash ROIC |
(51.93%) | (73.12%) | (22.36%) | (82.42%) | (81.81%) | (110.51%) | (314.98%) | (32.98%) | (7.93%) | (18.39%) |
Accounts Receivable Turnover |
0.00 | 0.00 | — | — | — | — | — | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(17,634.78) | (13,489.44) | (5,499.50) | (1,937.49) | (1,426.60) | (841.57) | (618.95) | (23.81) | (0.97) | (0.91) |
Capex per Share |
80.11 | (5.00) | (7.60) | (0.92) | (0.54) | (0.41) | (0.12) | 0.01 | 0.00 | 0.00 |
Average Receivables |
0.06 | 0.06 | — | — | — | — | — | — | — | — |
Average Payables |
0.85 | 0.67 | 0.68 | 1.21 | 1.21 | 0.81 | 0.65 | 1.26 | 2.62 | 4.60 |
Average Assets |
48.16 | 16.62 | 11.61 | 9.85 | 6.62 | 6.43 | 4.70 | 7.54 | 54.19 | 100.46 |
Average Common Equity |
38.78 | 13.01 | 10.33 | 7.77 | 4.20 | 4.44 | 2.87 | 4.80 | 50.05 | 94.53 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Columns are period end dates